CAF                                                 prostate(128)
 _________________________________________________________________
  cytoxan......... 150 mg/sqm/day orally from day 3 to day 6.
  adriamycin...... 30 mg/sqm IV day 1.
  fluorouracil.... 400 mg/sqm IV on days 1 and 8.
  FREQUENCY....... Repeat cycle every 4 weeks.


  reference...
    Chlebowski RT.  Hestorff R.  Sardoff L.  Weiner J.  Bateman 
    JR. Cyclophosphamide (NSC 26271) versus the combination of 
    adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and 
    cyclophosphamide in the treatment of metastatic prostatic 
    cancer: a randomized trial. Cancer.  42(6):2546-52, 1978 Dec. 
  abstract...
    Twenty-seven patients with a diagnosis of metastatic 
    adenocarcinoma of the prostate were treated in a randomized, 
    prospective trial with either Cyclophosphamide or a 
    combination of Adriamycin, 5-Fluorouracil, and 
    Cyclophosphamide. Doses were either Cyclophosphamide alone 
    (800-1200 mg/m2 iv q 3 weeks) or Cyclophosphamide (150-200 
    mg/m2 po Day 3-6) plus 5-FU (400-500 mg/m2 iv Day 1, 8) plus 
    Adriamycin (30-50 mg/m2 iv Day 1) given as a 4 week treatment 
    cycle. Patients with compromised bone marrow reserve initially 
    received the lower dose level. Objectively stable disease as 
    defined by a modification of the National Prostatic Cancer 
    Project criteria was seen in 53% of the 15 Cyclophosphamide 
    treated patients and in 50% of the 12 combination treated 
    patients. Survival was not significantly different in the two 
    arms. However, the survival of patients responding to 
    Cyclophosphamide was significantly longer than that of 
    patients responding to the combination (median 18.6 months 
    versus 8.1 months, p less than 0.05). Gastrointestinal and 
    hematologic toxicity was moderate with both regimens. 
    Therefore, in the present study, Cyclophosphamide alone was as 
    effective as the combination of Cyclophosphamide, 5-FU and 
    Adriamycin for patients with disseminated prostatic carcinoma. 
    The moderate hematologic toxicity noted with both regimens 
    suggests further evaluation of drug combinations utilizing 
    higher dosages of active agents in this disease.